Results 291 to 300 of about 81,723 (303)

Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib

Journal of the American Academy of Dermatology, 2017
Deep Joshipura, Yana Turkowski, Victor Huang   +2 more
exaly  

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study

Journal of the American Academy of Dermatology, 2016
Ka Papp, James G Krueger, Hideshi Torii
exaly  

A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease

Clinical Gastroenterology and Hepatology, 2014
Subrata Ghosh, Olivier Dewit, Paolo Gionchetti   +2 more
exaly  

Immune-globulin/immunosuppressants/Janus-kinase-inhibitors

Reactions Weekly, 2022
openaire   +1 more source

Janus kinase inhibitor-related thromboembolic events

Reactions Weekly, 2021
openaire   +1 more source

Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate

Journal of the American Academy of Dermatology, 2015
Brett A King
exaly  

Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure

Journal of the American Academy of Dermatology, 2017
Lucy Y Liu, James P Strassner
exaly  

A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Clinical Lymphoma, Myeloma and Leukemia, 2015
Naveen Pemmaraju, Hagop M Kantarjian, Jorge Eduardo Cortes   +2 more
exaly  

Synthesis of a Janus Kinase Inhibitor

Synfacts, 2020
openaire   +1 more source

Ruxolitinib: An Oral Janus Kinase 1 and Janus Kinase 2 Inhibitor in the Management of Myelofibrosis

Postgraduate Medicine, 2013
Srdan Verstovsek,,, of Medicine
exaly